NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

May 1, 2025

Conditions

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic SclerosisSjogren's SyndromeRheumatoid ArthritisImmune ThrombocytopeniaPrimary Biliary Cholangitis

Interventions

BIOLOGICAL

T cell injection targeting CD19 chimeric antigen receptor

Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.